For Harvard University, which boasts an endowment of over $37 billion, a $20 million contribution is appreciated, but far from a game-changer.  

Still, that's the amount that Merck paid the ivy league institution to obtain the rights of a potentially revolutionary group of cancer drugs that campus researchers have been working on. It's the biggest drug licensing deal that Harvard has ever entered.  

The university will also be due royalties in the event that the experimental medication becomes a big money-maker.  

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.